On April 28, 2005, the FDA's approval of exenatide (Byetta) made it the first GLP-1 receptor agonist approved for clinical use
Step 3: FDA Review Period (6 to 10 Months) Once the FDA accepts the NDA for review, it has 10 months for a Standard Review or 6 months for a Priority Review
Treatments for the condition appear to offer only temporary benefits, according to MedlinePlus, the authoritative source that gathers health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations
In contrast to the stimulation of ghrelin observed in mice, intragastric administration of another bitter tastant, quinine-hydrochloride (HCl quinine, 10 umol/kg), reduced fasting plasma ghrelin and motilin levels in healthy women (22, 63), associated with increased activity in hedonic and homeostatic brain regions on functional magnetic resonance imaging, and suppressed antral motility and energy intake (22)
Zheng et al
Vd is ~0.5 L/kg (extracellular volume)